CoChat
Sign Up
Cited by 47Sphingolipid Metabolism and SignalingAlzheimer's disease research and treatmentsLysosomal Storage Disorders Research

Diverse roles of ceramide in the progression and pathogenesis of Alzheimer's disease

Open access
Md Riad Chowdhury, Hee Kyung Jin, Jae‐sung Bae·2022·Biomedicines
DOI 10.3390/biomedicines10081956PMC PMC9406151
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer’s disease (AD) is the most common neurodegenerative disorder, and is associated with several pathophysiological features, including cellular dysfunction, failure of neurotransmission, cognitive impairment, cell death, and other clinical consequences. Advanced research on the pathogenesis of AD has elucidated a mechanistic framework and revealed many therapeutic possibilities. Among the mechanisms, sphingolipids are mentioned as distinctive mediators to be associated with the pathology of AD. Reportedly, alteration in the metabolism of sphingolipids and their metabolites result in the dysfunction of mitochondria, autophagy, amyloid beta regulation, and neuronal homeostasis, which exacerbates AD progression. Considering the importance of sphingolipids, in this review, we discuss the role of ceramide, a bioactive sphingolipid metabolite, in the progression and pathogenesis of AD. Herein, we describe the ceramide synthesis pathway and its involvement in the dysregulation of homeostasis, which eventually leads to AD. Furthermore, this review references different therapeutics proposed to modulate the ceramide pathway to maintain ceramide levels and prevent the disease progression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

OpenAlex · 10.3390/biomedicines10081956

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 92

  1. [1]Jackson G.A. Dementia: Alzheimer’s Disease Nurs. Times 2002 98 32 34 10.1186/1472-6874-4-S1-S20/FIGURES/4 12479145 · DOI
  2. [2]Srivastava S. Ahmad R. Khare S.K. Alzheimer’s disease and its treatment by different approaches: A review Eur. J. Med. Chem. 2021 216 113320 10.1016/j.ejmech.2021.113320 33652356 · DOI
  3. [3]Galle S.A. Geraedts I. Deijen J. Milders M. Drent M. The Interrelationship between Insulin-Like Growth Factor 1, Apolipoprotein E Ε4, Lifestyle Factors, and The Aging Body and Brain J. Prev. Alzheimer’s Dis. 2020 7 256 273 10.14283/jpad.2020.11 32920629 · DOI
  4. [4]Shah R.S. Lee H.-G. Xiongwei Z. Perry G. Smith M.A. Castellani R.J. Current approaches in the treatment of Alzheimer’s disease Biomed. Pharmacother. 2008 62 199 207 10.1016/j.biopha.2008.02.005 18407457 · DOI
  5. [5]Brodowicz J. Przegaliński E. Müller C.P. Filip M. Ceramide and Its Related Neurochemical Networks as Targets for Some Brain Disorder Therapies Neurotox. Res. 2017 33 474 484 10.1007/s12640-017-9798-6 28842833 PMC5766709 · DOI
  6. [6]Park M.H. Jin H.K. Bae J.-S. Potential therapeutic target for aging and age-related neurodegenerative diseases: The role of acid sphingomyelinase Exp. Mol. Med. 2020 52 380 389 10.1038/s12276-020-0399-8 32203096 PMC7156489 · DOI · Paper page
  7. [7]Chakrabarti S.S. Bir A. Poddar J. Sinha M. Ganguly A. Chakrabarti S. Ceramide and Sphingosine-1-Phosphate in Cell Death Pathways: Relevance to the Pathogenesis of Alzheimer’s Disease Curr. Alzheimer Res. 2016 13 1232 1248 10.2174/1567205013666160603004239 27335046 · DOI
  8. [8]Kitatani K. Idkowiak-Baldys J. Hannun Y.A. The sphingolipid salvage pathway in ceramide metabolism and signaling Cell. Signal. 2008 20 1010 1018 10.1016/j.cellsig.2007.12.006 18191382 PMC2422835 · DOI
  9. [9]Crivelli S.M. Giovagnoni C. Visseren L. Scheithauer A.-L. de Wit N. Hoedt S.D. Losen M. Mulder M.T. Walter J. de Vries H.E. Sphingolipids in Alzheimer’s disease, how can we target them? Adv. Drug Deliv. Rev. 2020 159 214 231 10.1016/j.addr.2019.12.003 31911096 · DOI
  10. [10]Mielke M.M. Bandaru V.V.R. Haughey N.J. Xia J. Fried L.P. Yasar S. Albert M. Varma V. Harris G. Schneider E.B. Serum ceramides increase the risk of Alzheimer disease: The Women’s Health and Aging Study II Neurology 2012 79 633 641 10.1212/WNL.0b013e318264e380 22815558 PMC3414665 · DOI
  11. [11]Han X. Rozen S.G. Boyle S.H. Hellegers C. Cheng H. Burke J. Welsh-Bohmer K.A. Doraiswamy P.M. Kaddurah-Daouk R. Metabolomics in Early Alzheimer’s Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics PLoS ONE 2011 6 e21643 10.1371/journal.pone.0021643 21779331 PMC3136924 · DOI · Paper page
  12. [12]Kosicek M. Zetterberg H. Andreasen N. Peter-Katalinic J. Hecimovic S. Elevated Cerebrospinal Fluid Sphingomyelin Levels in Prodromal Alzheimer’s Disease Neurosci. Lett. 2012 516 302 305 10.1016/j.neulet.2012.04.019 22521584 · DOI
  13. [14]Chen Y.-G. Research Progress in the Pathogenesis of Alzheimer’s Disease Chin. Med. J. 2018 131 1618 1624 10.4103/0366-6999.235112 29941717 PMC6032682 · DOI
  14. [15]Shimada H. Kitamura S. Shinotoh H. Endo H. Niwa F. Hirano S. Kimura Y. Zhang M. Kuwabara S. Suhara T. Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer’s disease spectrum brains: A [ 11 C]PBB3-PET study Alzheimer’s Dement. Diagn. Assess. Dis. Monit. 2016 6 11 20 10.1016/j.jalz.2016.06.998 PMC5257028 28138509 · DOI
  15. [16]Kempf S.J. Metaxas A. Neurofibrillary tangles in Alzheimer′s disease: Elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics Neural Regen. Res. 2016 11 1579 1581 10.4103/1673-5374.193234 27904486 PMC5116834 · DOI
  16. [17]Poorkaj P. Kas A. D’Souza I. Zhou Y. Pham Q. Stone M. Olson M.V. Schellenberg G.D. A genomic sequence analysis of the mouse and human microtubule-associated protein tau Mamm. Genome 2001 12 700 712 10.1007/s00335-001-2044-8 11641718 · DOI
  17. [19]Wang W. Zhao F. Ma X. Perry G. Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances Mol. Neurodegener. 2020 15 30 10.1186/s13024-020-00376-6 32471464 PMC7257174 · DOI · Paper page
  18. [20]Lee S. Sato Y. Nixon R.A. Primary lysosomal dysfunction causes cargo-specific deficits of axonal transport leading to Alzheimer-like neuritic dystrophy Autophagy 2011 7 1562 1563 10.4161/auto.7.12.17956 22024748 PMC3327621 · DOI
  19. [21]Chan R.B. Oliveira T.G. Cortes E.P. Honig L.S. Duff K.E. Small S.A. Wenk M.R. Shui G. Di Paolo G. Comparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer Disease J. Biol. Chem. 2012 287 2678 2688 10.1074/jbc.M111.274142 22134919 PMC3268426 · DOI · Paper page
  20. [22]Grimm M. Grimm H.S. Pätzold A.J. Zinser E.G. Halonen R. Duering M. Tschäpe J.-A. De Strooper B. Müller U. Shen J. Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin Nat. Cell Biol. 2005 7 1118 1123 10.1038/ncb1313 16227967 · DOI
  21. [23]Mori T. Paris D. Town T. Rojiani A.M. Sparks D.L. Delledonne A. Crawford F. Abdullah L.I. Humphrey J.A. Dickson D.W. Cholesterol Accumulates in Senile plaques of Alzheimer Disease patients and in Transgenic APPswMice J. Neuropathol. Exp. Neurol. 2001 60 778 785 10.1093/jnen/60.8.778 11487052 · DOI
  22. [24]Fassbender K. Simons M. Bergmann C. Stroick M. Lütjohann D. Keller P. Runz H. Kühl S. Bertsch T. von Bergmann K. Simvastatin Strongly Reduces Levels of Alzheimer’s Disease β-Amyloid Peptides Aβ42 and Aβ40 In Vitro and In Vivo Proc. Natl. Acad. Sci. USA 2001 98 5856 5861 10.1073/pnas.081620098 11296263 PMC33303 · DOI
  23. [25]Matsuzaki K. Kato K. Yanagisawa K. Aβ polymerization through interaction with membrane gangliosides Biochim. Biophys. Acta (BBA) Mol. Cell Biol. Lipids 2010 1801 868 877 10.1016/j.bbalip.2010.01.008 20117237 · DOI
  24. [26]Mandon E. Ehses I. Rother J. van Echten G. Sandhoff K. Subcellular localization and membrane topology of serine palmitoyltransferase, 3-dehydrosphinganine reductase, and sphinganine N-acyltransferase in mouse liver J. Biol. Chem. 1992 267 11144 11148 10.1016/S0021-9258(19)49887-6 1317856 · DOI
  25. [27]Rao R.P. Vaidyanathan N. Rengasamy M. Oommen A.M. Somaiya N. Jagannath M.R. Sphingolipid Metabolic Pathway: An Overview of Major Roles Played in Human Diseases J. Lipids 2013 2013 1 12 PMC3747619 23984075
  26. [28]Sugimoto Y. Sakoh H. Yamada K. IPC Synthase as a Useful Target for Antifungal Drugs Curr. Drug Targets Infect. Disord. 2004 4 311 322 10.2174/1568005043340597 15578972 · DOI
  27. [29]Kitatani K. Sheldon K. Rajagopalan V. Anelli V.V. Jenkins R.W. Sun Y. Grabowski G.A. Obeid L. Hannun Y.A. Involvement of Acid β-Glucosidase 1 in the Salvage Pathway of Ceramide Formation J. Biol. Chem. 2009 284 12972 12978 10.1074/jbc.M802790200 19279011 PMC2676029 · DOI
  28. [30]Quintern L. Schuchman E. Levran O. Suchi M. Ferlinz K. Reinke H. Sandhoff K. Desnick R. Isolation of cDNA clones encoding human acid sphingomyelinase: Occurrence of alternatively processed transcripts EMBO J. 1989 8 2469 2473 10.1002/j.1460-2075.1989.tb08382.x 2555181 PMC401234 · DOI
  29. [31]Smith E.R. Merrill A.H. Differential Roles of de Novo Sphingolipid Biosynthesis and Turnover in the “Burst” of Free Sphingosine and Sphinganine, and Their 1-Phosphates and N-Acyl-Derivatives, That Occurs upon Changing the Medium of Cells in Culture (∗) J. Biol. Chem. 1995 270 18749 18758 10.1074/jbc.270.32.18749 7642524 · DOI
  30. [32]Moro K. Nagahashi M. Gabriel E. Takabe K. Wakai T. Clinical application of ceramide in cancer treatment Breast Cancer 2019 26 407 415 10.1007/s12282-019-00953-8 30963461 PMC7315770 · DOI
  31. [33]Kolter T. Sandhoff K. Principles of Lysosomal Membrane Digestion: Stimulation of Sphingolipid Degradation by Sphingolipid Activator Proteins and Anionic Lysosomal Lipids Annu. Rev. Cell Dev. Biol. 2005 21 81 103 10.1146/annurev.cellbio.21.122303.120013 16212488 · DOI · Paper page
  32. [34]Brothers H.M. Gosztyla M. Robinson S.R. The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer’s Disease Front. Aging Neurosci. 2018 10 118 10.3389/fnagi.2018.00118 29922148 PMC5996906 · DOI · Paper page
  33. [35]Takahashi R.H. Nagao T. Gouras G.K. Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer’s disease Pathol. Int. 2017 67 185 193 10.1111/pin.12520 28261941 · DOI
  34. [37]Mouton R.E. Venable M.E. Ceramide induces expression of the senescence histochemical marker, β-galactosidase, in human fibroblasts Mech. Ageing Dev. 2000 113 169 181 10.1016/S0047-6374(99)00105-0 10714936 · DOI · Paper page
  35. [38]Puglielli L. Ellis B.C. Saunders A.J. Kovacs D.M. Ceramide Stabilizes β-Site Amyloid Precursor Protein-cleaving Enzyme 1 and Promotes Amyloid β-Peptide Biogenesis J. Biol. Chem. 2003 278 19777 19783 10.1074/jbc.M300466200 12649271 · DOI
  36. [39]Liu F. Lu J. Manaenko A. Tang J. Hu Q. Mitochondria in Ischemic Stroke: New Insight and Implications Aging Dis. 2018 9 924 937 10.14336/AD.2017.1126 30271667 PMC6147588 · DOI
  37. [40]Norat P. Soldozy S. Sokolowski J.D. Gorick C.M. Kumar J.S. Chae Y. Yağmurlu K. Prada F. Walker M. Levitt M.R. Mitochondrial dysfunction in neurological disorders: Exploring mitochondrial transplantation NPJ Regen. Med. 2020 5 1 9 10.1038/s41536-020-00107-x 33298971 PMC7683736 · DOI
  38. [41]Kogot-Levin A. Saada A. Ceramide and the mitochondrial respiratory chain Biochimie 2014 100 88 94 10.1016/j.biochi.2013.07.027 23933096 · DOI
  39. [43]Finsterer J. Cognitive dysfunction in mitochondrial disorders Acta Neurol. Scand. 2012 126 1 11 10.1111/j.1600-0404.2012.01649.x 22335339 · DOI
  40. [44]Adams J. Probable Causes of Alzheimer’s Disease Science 2021 3 16 10.3390/sci3010016 · DOI
  41. [45]Khacho M. Clark A. Svoboda D.S. Maclaurin J.G. Lagace D.C. Park D. Slack R.S. Mitochondrial dysfunction underlies cognitive defects as a result of neural stem cell depletion and impaired neurogenesis Hum. Mol. Genet. 2017 26 3327 3341 10.1093/hmg/ddx217 28595361 PMC5886206 · DOI
  42. [47]Trayssac M. Hannun Y.A. Obeid L.M. Role of sphingolipids in senescence: Implication in aging and age-related diseases J. Clin. Investig. 2018 128 2702 2712 10.1172/JCI97949 30108193 PMC6025964 · DOI
  43. [48]Peacocke M. Campisi J. Cellular senescence: A reflection of normal growth control, differentiation, or aging? J. Cell. Biochem. 1991 45 147 155 10.1002/jcb.240450205 2055943 · DOI
  44. [49]Venable M.E. Lee J.Y. Smyth M.J. Bielawska A. Obeid L.M. Role of Ceramide in Cellular Senescence J. Biol. Chem. 1995 270 30701 30708 10.1074/jbc.270.51.30701 8530509 · DOI
  45. [50]Chalfant C.E. Kishikawa K. Mumby M.C. Kamibayashi C. Bielawska A. Hannun Y.A. Long Chain Ceramides Activate Protein Phosphatase-1 and Protein Phosphatase-2A J. Biol. Chem. 1999 274 20313 20317 10.1074/jbc.274.29.20313 10400653 · DOI
  46. [51]Lee J. Bielawska A. Obeid L. Regulation of Cyclin-Dependent Kinase 2 Activity by Ceramide Exp. Cell Res. 2000 261 303 311 10.1006/excr.2000.5028 11112337 · DOI
  47. [52]Mahady L.J. He B. Malek-Ahmadi M. Mufson E.J. Telomeric alterations in the default mode network during the progression of Alzheimer’s disease: Selective vulnerability of the precuneus Neuropathol. Appl. Neurobiol. 2020 47 428 440 10.1111/nan.12672 33107640 · DOI
  48. [53]Thadathil N. Delotterie D.F. Xiao J. Hori R. McDonald M.P. Khan M.M. DNA Double-Strand Break Accumulation in Alzheimer’s Disease: Evidence from Experimental Models and Postmortem Human Brains Mol. Neurobiol. 2020 58 118 131 10.1007/s12035-020-02109-8 32895786 PMC13252816 · DOI · Paper page
  49. [56]Jiang W. Ogretmen B. Autophagy paradox and ceramide Biochim. Biophys. Acta (BBA) Mol. Cell Biol. Lipids 2013 1841 783 792 10.1016/j.bbalip.2013.09.005 24055889 PMC3960371 · DOI
  50. [57]Lee K.M. Hwang S.K. Lee J.A. Neuronal Autophagy and Neurodevelopmental Disorders Exp. Neurobiol. 2013 22 133 10.5607/en.2013.22.3.133 24167408 PMC3807000 · DOI
  51. [58]Young M.M. Kester M. Wang H.G. Sphingolipids: Regulators of Crosstalk between Apoptosis and Autophagy J. Lipid Res. 2013 54 5 19 10.1194/jlr.R031278 23152582 PMC3520539 · DOI
  52. [59]Scarlatti F. Bauvy C. Ventruti A. Sala G. Cluzeaud F. Vandewalle A. Ghidoni R. Codogno P. Ceramide-Mediated Macroautophagy Involves Inhibition of Protein Kinase B and up-Regulation of Beclin 1 J. Biol. Chem. 2004 279 18384 18391 10.1074/jbc.M313561200 14970205 · DOI
  53. [60]Qian W. Liu J. Jin J. Ni W. Xu W. Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1 Leuk. Res. 2007 31 329 339 10.1016/j.leukres.2006.06.021 16882451 · DOI
  54. [61]Li D. Wang L. Deng R. Tang J. Shen Y. Guo J.-F. Wang Y. Xia L.-P. Feng G.-K. Liu Q.-Q. The Pivotal Role of C-Jun NH2-Terminal Kinase-Mediated Beclin 1 Expression during Anticancer Agents-Induced Autophagy in Cancer Cells Oncogene 2009 28 886 898 10.1038/onc.2008.441 19060920 · DOI
  55. [62]Koike M. Shibata M. Tadakoshi M. Gotoh K. Komatsu M. Waguri S. Kawahara N. Kuida K. Nagata S. Kominami E. Inhibition of Autophagy Prevents Hippocampal Pyramidal Neuron Death after Hypoxic-Ischemic Injury Am. J. Pathol. 2008 172 454 469 10.2353/ajpath.2008.070876 18187572 PMC2312361 · DOI · Paper page
  56. [63]Cheng J. North B.J. Zhang T. Dai X. Tao K. Guo J. Wei W. The emerging roles of protein homeostasis-governing pathways in Alzheimer’s disease Aging Cell 2018 17 e12801 10.1111/acel.12801 29992725 PMC6156496 · DOI
  57. [64]Nixon R.A. Wegiel J. Kumar A. Yu W.H. Peterhoff C. Cataldo A. Cuervo A.M. Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study J. Neuropathol. Exp. Neurol. 2005 64 113 122 10.1093/jnen/64.2.113 15751225 · DOI · Paper page
  58. [65]Yu J. Pan W. Shi R. Yang T. Li Y. Yu G. Bai Y. Schuchman E.H. He X. Zhang G. Ceramide is Upregulated and Associated with Mortality in Patients with Chronic Heart Failure Can. J. Cardiol. 2015 31 357 363 10.1016/j.cjca.2014.12.007 25746025 · DOI
  59. [66]Kurtishi A. Rosen B. Patil K.S. Alves G.W. Møller S.G. Cellular Proteostasis in Neurodegeneration Mol. Neurobiol. 2018 56 3676 3689 10.1007/s12035-018-1334-z 30182337 · DOI
  60. [67]Nilsson P. Saido T.C. Dual roles for autophagy: Degradation and secretion of Alzheimer’s disease Aβ peptide BioEssays 2014 36 570 578 10.1002/bies.201400002 24711225 PMC4316186 · DOI
  61. [68]Li Q. Liu Y. Sun M. Autophagy and Alzheimer’s Disease Cell. Mol. Neurobiol. 2016 37 377 388 10.1007/s10571-016-0386-8 27260250 PMC11482122 · DOI
  62. [69]Mielke M.M. Haughey N.J. Han D. An Y. Bandaru V.V.R. Lyketsos C.G. Ferrucci L. Resnick S.M. The Association between Plasma Ceramides and Sphingomyelins and Risk of Alzheimer’s Disease Differs by Sex and APOE in the Baltimore Longitudinal Study of Aging J. Alzheimer’s Dis. 2017 60 819 828 10.3233/JAD-160925 28035934 PMC5493514 · DOI
  63. [70]Meeusen J.W. Donato L.J. Bryant S.C. Baudhuin L.M. Berger P.B. Jaffe A.S. Plasma Ceramides: A Novel Predictor of Major Adverse Cardiovascular Events After Coronary Angiography Arterioscler. Thromb. Vasc. Biol. 2018 38 1933 1939 10.1161/ATVBAHA.118.311199 29903731 · DOI
  64. [71]Sevush S. Jy W. Horstman L.L. Mao W.-W. Kolodny L. Ahn Y.S. Platelet Activation in Alzheimer Disease Arch. Neurol. 1998 55 530 536 10.1001/archneur.55.4.530 9561982 · DOI
  65. [72]Kim M. Nevado-Holgado A. Whiley L. Snowden S.G. Soininen H. Kloszewska I. Mecocci P. Tsolaki M. Vellas B. Thambisetty M. Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer’s Disease J. Alzheimer’s Dis. 2017 60 809 817 10.3233/JAD-160645 27911300 PMC5676755 · DOI
  66. [73]De Mello V.D.F. Lankinen M. Schwab U. Kolehmainen M. Lehto S. Seppänen-Laakso T. Oresic M. Pulkkinen L. Uusitupa M. Erkkilä A.T. Link between plasma ceramides, inflammation and insulin resistance: Association with serum IL-6 concentration in patients with coronary heart disease Diabetologia 2009 52 2612 2615 10.1007/s00125-009-1482-9 19669729 · DOI
  67. [74]Boon J. Hoy A.J. Stark R. Brown R.D. Meex R.C. Henstridge D.C. Schenk S. Meikle P.J. Horowitz J.F. Kingwell B.A. Ceramides Contained in LDL Are Elevated in Type 2 Diabetes and Promote Inflammation and Skeletal Muscle Insulin Resistance Diabetes 2013 62 401 410 10.2337/db12-0686 23139352 PMC3554351 · DOI
  68. [75]De Souza C.T. Araujo E.P. Bordin S. Ashimine R. Zollner R.L. Boschero A.C. Saad M.J.A. Velloso L.A. Consumption of a Fat-Rich Diet Activates a Proinflammatory Response and Induces Insulin Resistance in the Hypothalamus Endocrinology 2005 146 4192 4199 10.1210/en.2004-1520 16002529 · DOI · Paper page
  69. [77]Talbot K. Wang H.Y. Kazi H. Han L.Y. Bakshi K.P. Stucky A. Fuino R.L. Kawaguchi K.R. Samoyedny A.J. Wilson R.S. Demonstrated Brain Insulin Resistance in Alzheimer’s Disease Patients is Associated with IGF-1 Resistance, IRS-1 Dysregulation, and Cognitive Decline J. Clin. Investig. 2012 122 1316 1338 10.1172/JCI59903 22476197 PMC3314463 · DOI · Paper page
  70. [78]Gulbins E. Walter S. Becker K.A. Halmer R. Liu Y. Reichel M. Edwards M.J. Müller C.P. Fassbender K. Kornhuber J. A central role for the acid sphingomyelinase/ceramide system in neurogenesis and major depression J. Neurochem. 2015 134 183 192 10.1111/jnc.13145 25925550 · DOI
  71. [79]Xing Y. Tang Y. Zhao L. Wang Q. Qin W. Zhang J.-L. Jia J. Plasma Ceramides and Neuropsychiatric Symptoms of Alzheimer’s Disease J. Alzheimer’s Dis. 2016 52 1029 1035 10.3233/JAD-151158 27079712 · DOI
  72. [80]Dowlati Y. Herrmann N. Swardfager W. Liu H. Sham L. Reim E.K. Lanctôt K.L. A Meta-Analysis of Cytokines in Major Depression Biol. Psychiatry 2010 67 446 457 10.1016/j.biopsych.2009.09.033 20015486 · DOI · Paper page
  73. [81]Wadsworth J.M. Clarke D.J. McMahon S.A. Lowther J.P. Beattie A.E. Langridge-Smith P.R.R. Broughton H.B. Dunn T.M. Naismith J.H. Campopiano D.J. The Chemical Basis of Serine Palmitoyltransferase Inhibition by Myriocin J. Am. Chem. Soc. 2013 135 14276 14285 10.1021/ja4059876 23957439 · DOI
  74. [82]Mandala S.M. Frommer B.R. Thornton R.A. Kurtz M.B. Young N.M. Cabello M.A. Genilloud O. Liesch J.M. Smith J.L. Horn W.S. Inhibition of serine palmitoyl-transferase activity by lipoxamycin J. Antibiot. 1994 47 376 379 10.7164/antibiotics.47.376 8175492 · DOI
  75. [83]Triola G. Fabria G. Llebaria A. Synthesis of a Cyclopropene Analogue of Ceramide, a Potent Inhibitor of Dihydroceramide Desaturase Angew. Chem. Int. Ed. 2001 40 1960 1962 10.1002/1521-3773(20010518)40:10<1960::AID-ANIE1960>3.0.CO;2-V 11385686 · DOI
  76. [84]Munoz-Olaya J.M. Matabosch X. Bedia C. Egido-Gabás M. Casas J. Llebaria A. Delgado A. Fabriàs G. Synthesis and Biological Activity of a Novel Inhibitor of Dihydroceramide Desaturase ChemMedChem 2008 3 946 953 10.1002/cmdc.200700325 18236489 · DOI
  77. [85]Skácel J. Slusher B.S. Tsukamoto T. Small Molecule Inhibitors Targeting Biosynthesis of Ceramide, the Central Hub of the Sphingolipid Network J. Med. Chem. 2021 64 279 297 10.1021/acs.jmedchem.0c01664 33395289 PMC8023021 · DOI
  78. [86]Zweerink M. Edison A. Wells G. Pinto W. Lester R. Characterization of a novel, potent, and specific inhibitor of serine palmitoyltransferase J. Biol. Chem. 1992 267 25032 25038 10.1016/S0021-9258(19)74001-0 1460005 · DOI
  79. [87]Merrill A. Schmelza E.M. Dillehay D. Spiegel S. Shayman J. Schroeder J. Riley R. Voss K. Wang E. Sphingolipids—The Enigmatic Lipid Class: Biochemistry, Physiology, and Pathophysiology Toxicol. Appl. Pharmacol. 1997 142 208 225 10.1006/taap.1996.8029 9007051 · DOI
  80. [88]Nara F. Tanakaa M. Hosoyab T. Suzuki-Konagaia K. Ogita T. Scyphostatin, a neutral sphingomyelinase inhibitor from a discomycete, Trichopeziza mollissima: Taxonomy of the producing organism, fermentation, isolation, and physico-chemical properties J. Antibiot. 1999 52 525 530 10.7164/antibiotics.52.525 10470675 · DOI
  81. [89]Arenz C. Giannis A. Synthesis of the First Selective Irreversible Inhibitor of Neutral Sphingomyelinase Angew. Chem. Int. Ed. 2000 39 1440 1442 10.1002/(SICI)1521-3773(20000417)39:8<1440::AID-ANIE1440>3.0.CO;2-R 10777634 · DOI
  82. [90]Arenz C. Thutewohl M. Block O. Waldmann H. Altenbach H.-J. Giannis A. Manumycin A and Its Analogues are Irreversible Inhibitors of Neutral Sphingomyelinase Chembiochem 2001 2 141 143 10.1002/1439-7633(20010202)2:2<141::AID-CBIC141>3.0.CO;2-P 11828438 · DOI
  83. [91]Uchida R. Tomoda H. Dong Y. Omura S. Alutenusin, a specific neutral sphingomyelinase inhibitor, produced by Penicillium sp. FO-7436 J. Antibiot. 1999 52 572 574 10.7164/antibiotics.52.572 10470682 · DOI
  84. [92]Martín S.F. Navarro F. Forthoffer N. Navas P. Villalba J.M. Neutral magnesium-dependent sphingomyelinase from liver plasma membrane: Purification and inhibition by ubiquinol J. Bioenerg. Biomembr. 2001 33 143 153 10.1023/A:1010704715979 11456220 · DOI
  85. [93]Park M.H. Park K.H. Choi B.J. Han W.H. Yoon H.J. Jung H.Y. Lee J. Song I.-S. Lim D.Y. Choi M.-K. Discovery of a dual-action small molecule that improves neuropathological features of Alzheimer’s disease mice Proc. Natl. Acad. Sci. USA 2022 119 e2115082119 10.1073/pnas.2115082119 35027452 PMC8784098 · DOI
  86. [94]Yang K. Yu J. Nong K. Wang Y. Niu A. Chen W. Dong J. Wang J. Discovery of Potent, Selective, and Direct Acid Sphingomyelinase Inhibitors with Antidepressant Activity J. Med. Chem. 2020 63 961 974 10.1021/acs.jmedchem.9b00739 31944697 · DOI
  87. [95]Darroch P.I. Dagan A. Granot T. He X. Gatt S. Schuchman E.H. A Lipid Analogue That Inhibits Sphingomyelin Hydrolysis and Synthesis, Increases Ceramide, and Leads to Cell Death J. Lipid Res. 2005 46 2315 2324 10.1194/jlr.M500136-JLR200 16150832 · DOI
  88. [96]Sakata A. Ochiai T. Shimeno H. Hikishima S. Yokomatsu T. Shibuya S. Toda A. Eyanagi R. Soeda S. Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice Immunology 2007 122 54 64 10.1111/j.1365-2567.2007.02612.x 17451462 PMC2265987 · DOI
  89. [97]Okudaira C. Ikeda Y. Kondo S. Furuya S. Hirabayashi Y. Koyano T. Saito Y. Umezawa K. Inhibition of Acidic Sphingomyelinase by Xanthone Compounds Isolated fromGarcinia Speciosa J. Enzym. Inhib. 2000 15 129 138 10.1080/14756360009030346 10938539 · DOI
  90. [98]Kölzer M. Arenz C. Ferlinz K. Werth N. Schulze H. Klingenstein R. Sandhoff K. Phosphatidylinositol-3,5-Bisphosphate is a Potent and Selective Inhibitor of Acid Sphingomyelinase Biol. Chem. 2003 384 1293 1298 10.1515/BC.2003.144 14515991 · DOI
  91. [99]Testai F.D. Landek M.A. Goswami R. Ahmed M. Dawson G. Acid sphingomyelinase and inhibition by phosphate ion: Role of inhibition by phosphatidyl-myo-inositol 3,4,5-triphosphate in oligodendrocyte cell signaling J. Neurochem. 2004 89 636 644 10.1046/j.1471-4159.2004.02374.x 15086520 · DOI
  92. [100]Kornhuber J. Tripal P. Gulbins E. Muehlbacher M. Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) Sphingolipids Basic Sci. Drug Dev. 2013 215 169 186 10.1007/978-3-7091-1368-4_9 23579455 · DOI

Cited by

Sorted by citations

Authors
Chowdhury, M. R., Jin, H. K., & Bae, J.
Affiliations
Kyungpook National University (KR)
Corresponding author
  • Hee Kyung Jin
  • Jae‐sung Bae
ORCID
Venue
Biomedicines
Publisher
MDPI AG
Published
2022-08-12
Volume
10
Issue
8
Pages
1956
ISSN
2227-9059 (ISSN-L)
DOI
10.3390/biomedicines10081956
PMC
PMC9406151
OpenAlex
W4291415384
Cited by
47
References
6
Citations by year
2026: 6 · 2025: 17 · 2024: 14 · 2023: 10
FWCI
1.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Korea government (MSIT) (2018M3C7A1056513, 2020R1A2C3006875, 2020R1A2C3006734)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
Keywords
ceramide, Alzheimer's disease, sphingolipids, mitochondrial dysfunction, autophagy, neuronal homeostasis, neurodegeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review